Ball Corporation Declares Quarterly Dividend

PR Newswire

WESTMINSTER, Colo., April 28, 2021 /PRNewswire/ — Ball Corporation’s (NYSE: BLL) board of directors today declared a cash dividend of 15 cents per share, payable June 15, 2021 to shareholders of record as of June 1, 2021.

Ball will announce its first quarter 2021 earnings on Thursday, May 6th 2021. Conference call details are below.

Ball Corporation supplies innovative, sustainable aluminum packaging solutions for beverage, personal care and household products customers, as well as aerospace and other technologies and services primarily for the U.S. government. Ball Corporation and its subsidiaries employ 21,500 people worldwide and reported 2020 net sales of $11.8 billion. For more information, visit www.ball.com, or connect with us on Facebook or Twitter.


Conference Call Details

The North American toll-free number for the call is 800-920-5564. International callers should dial +1 212-231- 2909. Please use the following URL for a webcast of the live call:

https://edge.media-server.com/mmc/p/569qbar7

For those unable to listen to the live call, a taped replay will be available from 11 a.m. Mountain time on May 6, 2021, until 11 a.m. Mountain time on May 13, 2021. To access the replay, call 800-633-8284 (North American callers) or +1 402-977-9140 (international callers) and use reservation number 21993264. A written transcript of the call will be posted within 48 hours of the call’s conclusion to Ball’s website at www.ball.com/investors under “news and presentations.”


Forward-Looking Statements

This release contains “forward-looking” statements concerning future events and financial performance. Words such as “expects,” “anticipates,” “estimates,” “believes,” and similar expressions typically identify forward-looking statements, which are generally any statements other than statements of historical fact. Such statements are based on current expectations or views of the future and are subject to risks and uncertainties, which could cause actual results or events to differ materially from those expressed or implied. You should therefore not place undue reliance upon any forward-looking statements and any such statements should be read in conjunction with, and qualified in their entirety by, the cautionary statements referenced below. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Key factors, risks and uncertainties that could cause actual outcomes and results to be different are summarized in filings with the Securities and Exchange Commission, including Exhibit 99 in our Form 10-K, which are available on our website and at www.sec.gov. Additional factors that might affect: a) our packaging segments include product capacity, supply, and demand constraints and fluctuations and changes in consumption patterns; availability/cost of raw materials, equipment, and logistics; competitive packaging, pricing and substitution; changes in climate and weather; footprint adjustments and other manufacturing changes, including the startup of new facilities and lines; failure to achieve synergies, productivity improvements or cost reductions; unfavorable mandatory deposit or packaging laws; customer and supplier consolidation; power and supply chain interruptions; changes in major customer or supplier contracts or loss of a major customer or supplier; political instability and sanctions; currency controls; changes in foreign exchange or tax rates; and tariffs, trade actions, or other governmental actions, including business restrictions and shelter-in-place orders in any country or jurisdiction affecting goods produced by us or in our supply chain, including imported raw materials; b) our aerospace segment include funding, authorization, availability and returns of government and commercial contracts; and delays, extensions and technical uncertainties affecting segment contracts; c) the Company as a whole include those listed above plus: the extent to which sustainability-related opportunities arise and can be capitalized upon; changes in senior management, succession, and the ability to attract and retain skilled labor; regulatory action or issues including tax, environmental, health and workplace safety, including U.S. FDA and other actions or public concerns affecting products filled in our containers, or chemicals or substances used in raw materials or in the manufacturing process; technological developments and innovations; the ability to manage cyber threats; litigation; strikes; disease; pandemic; labor cost changes; rates of return on assets of the Company’s defined benefit retirement plans; pension changes; uncertainties surrounding geopolitical events and governmental policies both in the U.S. and in other countries, including policies, orders, and actions related to COVID-19; reduced cash flow; interest rates affecting our debt; and successful or unsuccessful joint ventures, acquisitions and divestitures, and their effects on our operating results and business generally.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ball-corporation-declares-quarterly-dividend-301279602.html

SOURCE Ball Corporation

Bladex acts as Joint Lead Arranger in a US$300 million, Senior, Secured, Term Loan Facility for Investment Energy Resources Ltd.

PR Newswire

PANAMA CITY, April 28, 2021 /PRNewswire/ — Banco Latinoamericano de Comercio Exterior, S.A. (“Bladex” or the “Bank“) today announced the successful closing of a US$300 million 7-year senior secured term loan (the “Facility” or the “Loan“) for Investment Energy Resources Limited, the holding company of CMI Energía (“CMI Energía” or the “Company“) as part of a US$1.0 billion liability management exercise, thus optimizing the Company’s financial structure. The Facility is guaranteed by the Company’s main renewable energy projects/subsidiaries and secured by shares of the majority of such operating entities.

Owned by Corporación Multi Inversiones (“CMI” or the “Group“), one of Central America’s largest agro-industrial conglomerates with headquarters in Guatemala, CMI Energía is the leading renewable energy player in Central America operating a portfolio of over 800MW of renewable assets. The Company currently has presence in Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica and the Dominican Republic.

The Loan was structured as a club deal among Bladex, Banco Industrial and Banco Davivienda, acting together as Joint Lead Arrangers. Bladex also acted as Loan Documentation Coordinator and Administrative Agent under the Facility.

Jorge Salas, CEO of Bladex, stated: “Bladex is very pleased to have worked together with CMI and the other Joint Lead Arrangers in structuring this very important facility for CMI. The transaction attests to Bladex’s capabilities to work on higher value-added financial solutions for its customers, and is fully in line with the Bank’s focus on fostering growth and economic integration throughout Latin America. Moreover, this transaction has positive environmental benefits, which is something that we are increasingly looking to support as part of our business activities.”

The US$ 300 million Facility was issued concurrently with a US$ 700 million 2029 Reg S / 144A green bond (the “Bond“) to refinance debt from renewable energy projects. The Bond represents the Company’s debut to the green bond international markets, and the first corporate green bond from Central America & the Caribbean.  

Corporación Multi Inversiones is a family-owned multilatina company founded in 1920, with presence in 15 countries, operating two main business groups: CMI Foods, engaged in the milling and production of related consumer products, animal protein and operating fast-food restaurant chains (+1,000 restaurant locations, with Pollo Campero as the Group’s leading restaurant brand), and CMI Capital, which operates renewable energy and real estate projects in addition to the Group’s financial services business.    

Bladex, a multinational bank originally established by the central banks of Latin-American and Caribbean countries, began operations in 1979 to promote foreign trade and economic integration in the Region. The Bank, headquartered in Panama, also has offices in Argentina, Brazil, Colombia, Mexico, the United States of America, and a Representative License in Peru, supporting the regional expansion and servicing of its customer base, which includes financial institutions and corporations.

Bladex is listed on the NYSE in the United States of America (ticker symbol: BLX), since 1992, and its shareholders include: central banks, state-owned banks and entities representing 23 Latin American countries, commercial banks and financial institutions, and institutional and retail investors through its public listing.

For further information on Bladex, please access its website at www.bladex.com or contact:

Felipe Suárez – SVP, Head of Loan Structuring & Syndications
Head Office Address:  Torre V, Business Park, Avenida La Rotonda, Urb. Costa del Este, Panama, Republic of Panama

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bladex-acts-as-joint-lead-arranger-in-a-us300-million-senior-secured-term-loan-facility-for-investment-energy-resources-ltd-301279598.html

SOURCE Banco Latinoamericano de Comercio Exterior, S.A. (Bladex)

Agenus to Present at the 2021 ASCO Annual Meeting

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two presentations at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting poster sessions. The ASCO meeting will be held from June 4 – 8, 2021.

Presentation Details:

Abstract title: Differentiated activity profile for the PD-1 inhibitor balstilimab
Abstract number: 5529
Poster Session: Gynecologic Cancer
Presenting author: Cailin Joyce, PhD

Abstract title: Initial findings of the first-in-human Phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors
Abstract number: 2634
Poster Session: Developmental Therapeutics – Immunotherapy
Presenting author: Anthony Tolcher, MD

Full abstracts will be released on Wednesday, May 19. The 2021 ASCO Annual Meeting will take place virtually on June 4 – 8, 2021.


About balstilimab


Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market. Balstilimab is currently in clinical trials as monotherapy and in combination with Agenus’ anti-CTLA-4, zalifrelimab, in an ongoing Phase 2 study for recurrent/metastatic cervical cancer.

A Biologics License Application has been submitted to the U.S. Food and Drug Administration for the use of balstilimab to treat recurrent/metastatic cervical cancer.


About AGEN2373


AGEN2373 is a novel, fully human monoclonal conditionally active CD137 agonist antibody designed to selectively enhance CD137 co-stimulatory signaling in activated immune cells while mitigating side effects associated with systemic activation of CD137. CD137 (4-1BB) is a positive regulator of the immune system that is highly upregulated on activated T cells (adaptive immune cells) and NK cells (innate immune cells).

AGEN2373 is advancing in a Phase 1 clinical trial against solid tumors.


About Agenus


Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.


Forward-Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of balstilimab, an anti-PD-1, and AGEN2373. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Contact


Agenus Investor Relations

Jan Medina, CFA
Agenus
781-674-4490
[email protected]

Agenus Media Relations

Kimberly Ha
KKH Advisors
917-291-5744
[email protected]



Colorado Community College System not mandating COVID-19 vaccine for Fall 2021

Denver, April 28, 2021 (GLOBE NEWSWIRE) — Colorado Community College System (CCCS) Chancellor Joe Garcia announced today that CCCS will continue to follow recommendations of health authorities, but does not intend on mandating COVID-19 vaccines for all students, faculty, or staff for the Fall 2021 semester.

The system will continue to strongly encourage all students, faculty, and staff to not only get vaccinated, but to follow all other safety protocols. “The health and safety of the students, faculty, and staff is our top priority,” said Garcia. “Since the beginning of the pandemic, we have closely followed the recommendations of national, state, and local health authorities. We moved quickly to remote instruction and support face coverings, social distancing, testing, and quarantining when necessary, all while delivering on our mission and ensuring access for countless Coloradans.”

As community college students are more likely to work part-time or full-time jobs, be parents, and have limited resources, CCCS seeks to remove barriers to educational pursuits and serve all learners as student-ready institutions.

Online learning is still heavily used across CCCS colleges as a way to support social distancing protocols. For those who do attend class on campus, community college classes are small, typically about 20 students, and follow safety recommendations by health authorities.

The rural colleges that have residence halls and athletic teams may require students to be vaccinated for COVID-19, like other immunization requirements to participate in intercollegiate athletics or to live in residence halls. As with other vaccines, students with medical, religious, or personal reasons will have the option to request an exemption. 

 

###

About Colorado Community College System

The Colorado Community College System (CCCS) is the state’s largest system of higher education and workforce development, delivering thousands of programs to over 125,000 students annually through 13 colleges and 38 locations across Colorado. Our open-access mission ensures all Coloradans who aspire to enrich their lives have access to high quality, affordable higher education opportunities. The System Office provides leadership, advocacy, and support to the colleges under the direction of the State Board for Community Colleges and Occupational Education (SBCCOE). Join us in changing the way Colorado goes to college www.cccs.edu.



Fiona Lytle
Colorado Community College System
(720) 393-9824
[email protected]

Kontrol Technologies to Report Fiscal Year End 2020 Financial Results

PR Newswire

TORONTO, April 28, 2021 /PRNewswire/ – Kontrol Technologies Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) (“Kontrol Technologies” or “Kontrol” or “Company“) a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report  its Fiscal Year End 2020 financial results, for the period ended December 31st, 2020, on April 30th, 2021 (the “filing date”).  A complete set of the Financial Statements and Management’s Discussion & Analysis will also be filed on SEDAR (www.sedar.com) on the filing date.

A call to discuss the financial results has been scheduled for Friday, April 30th, 2021 at 4:30pm (EST). The event will be hosted by Paul Ghezzi, CEO and Claudio Del Vasto, CFO, of Kontrol Technologies Corp. We kindly request all participants to please connect at least 5 minutes prior to the event start time.

Event Details:


Title:

Kontrol Technologies Reports Fiscal Year End 2020 Financial Results


Event Date and Time:

April 30, 2021 4:30 PM Eastern


Event Duration:

60 Minutes


Event Link:


https://produceredition.webcasts.com/starthere.jsp?ei=1459147&tp_key=a3c7b20df9

 


Local / North American Toll-Free Call- in Numbers:

Confirmation #: 16477077

Local: 416-764-8609 (Toronto)

North American Toll Free: 888-390-0605

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Technologies provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. 

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking
statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. Kontrol

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date.  Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/kontrol-technologies-to-report-fiscal-year-end-2020-financial-results-301279617.html

SOURCE Kontrol Technologies Corp.

Norton Rose Fulbright appoints Ayşe Yüksel Mahfoud as Global Head of Corporate, M&A and Securities and Nick Grandage as Global Head of Banking and Finance

New York, April 28, 2021 (GLOBE NEWSWIRE) — Norton Rose Fulbright’s Global Chief Executive Gerry Pecht today appointed Ayşe Yüksel Mahfoud as Global Head of Corporate, M&A and Securities and Nick Grandage as Global Head of Banking and Finance.

A member of the firm’s Global Executive Committee, Ayşe works in both New York and Istanbul, serving as Partner-in-Charge of the Turkish office. Her experience in corporate transactions includes M&A, private equity, privatizations, joint ventures, strategic alliances, capital markets and SPAC transactions. She also advises on corporate governance issues.  Ayşe provides counsel to companies, private equity funds, sovereign wealth and other investment funds as well as financial institutions in cross-border transactions in the telecommunications, media, technology, retail, energy and infrastructure sectors.

Nick, who is based in London, has extensive experience acting on structured finance transactions globally, with a particular focus on the financing of international trade flows and transactions relating to the commodity sector. Nick represents banks, trading companies, insurers, FinTechs and intermediaries in transactions around the world, including deals involving energy, metals and soft commodities, as well as equipment and processed and semi-processed goods.  Nick has previously worked in Singapore, Hong Kong and New York.

Gerry Pecht, Norton Rose Fulbright’s Global Chief Executive, said:

“Ayşe and Nick are a real powerhouse duo – leading lawyers in important financial markets with significant depth of global experience. These appointments emphasize our firm prioritizing both our Corporate and our Banking and Finance practices globally. Ayşe and Nick will continue to grow these groups and enhance our offerings, ensuring our clients have a seamless and superior experience throughout the world.”

Ayşe Yüksel Mahfoud, Global Head of Corporate, M&A and Securities, said:

“Norton Rose Fulbright has a hugely talented cross-border Corporate, M&A and Securities practice, comprising more than 1,400 lawyers worldwide. I am looking forward to using my cross-border experience to serve our clients and develop our innovative corporate offerings globally.”

Nick Grandage, Global Head of Banking and Finance, said:

“With more than 800 lawyers across the world’s financial centers, our Banking and Finance practice is ideally positioned to offer innovative solutions to financial institutions and other clients. The banking and finance sector is transforming rapidly, and our global team will be at the forefront of providing client support through the changes ahead.”

Ayşe has been consistently ranked by Chambers Global. She was also named a “Woman of Influence” by by the New York Business Journal  in 2018 and a “Notable Women in Law” by Crain’s New York Business in 2019. Licensed in New York, Ayşe is an alumna of Columbia Law School and Harvard University.

Nick has been consistently recognized by both Chambers UK and The Legal 500. Nick is qualified in England and Wales and Hong Kong.


For further information, please contact:

Dan McKenna, US Director and Global Head of PR and Communications
Tel: +1 713 651 3576
[email protected]




Notes for editors:

 

Norton Rose Fulbright

Norton Rose Fulbright is a global law firm providing the world’s preeminent corporations and financial institutions with a full business law service. The firm has more than 4,000 lawyers and other legal staff based in Europe, the United States, Canada, Latin America, Asia, Australia, Africa and the Middle East.

Recognized for its industry focus, Norton Rose Fulbright is strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare. Through its global risk advisory group, the firm leverages its industry experience with its knowledge of legal, regulatory, compliance and governance issues to provide clients with practical solutions to the legal and regulatory risks facing their businesses.

Norton Rose Fulbright operates in accordance with its global business principles of quality, unity and integrity, aiming to provide the highest possible standard of legal service in each of its offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright Verein, a Swiss verein, helps coordinate the activities of Norton Rose Fulbright members but does not itself provide legal services to clients. Norton Rose Fulbright has offices in more than 50 cities worldwide, including London, Houston, New York, Toronto, Mexico City, Hong Kong, Sydney and Johannesburg. For more information, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com

Attachments



Andrew Ferraro
Norton Rose Fulbright
7136515235
[email protected]

Distinction Energy Corp. Announces Closing of Strategic Simonette Asset Acquisition

CALGARY, Alberta, April 28, 2021 (GLOBE NEWSWIRE) — Distinction Energy Corp. (“Distinction” or the “Company”) is pleased to announce that it has closed, together with Kiwetinohk Resources Corp. (“Kiwetinohk”), the previously announced $335 million acquisition (including $15 million in potential contingent payments based on future commodity prices) of certain interests in the Simonette area of northwest Alberta (the “Acquisition”).

Acquisition Details

The Acquisition consists of certain multi-zone, oil and liquids-rich natural gas producing assets in the Simonette area of northwest Alberta, including associated infrastructure and additional assets in the Willesden Green, Ferrier and other areas of Alberta. As of the fourth quarter of 2020, the assets were producing approximately 10,000 barrels of oil equivalent per day, weighted 43% to NGLs.

An independent reserves report on the Acquisition properties effective as of December 31, 2020 was prepared by McDaniel & Associates Consultants Ltd. (“McDaniel”), an independent qualified reserves evaluator, in accordance with National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities and the Canadian Oil and Gas Evaluation Handbook, in which 50% of the volumes and values represent the net working interest to Distinction of Proved Developed Producing Reserves of 13 MMboe (NPV10 $160 million), Proved Reserves of 30 MMboe (NPV10 $309 million) and 71 MMboe (NPV10 $548 million) on a Proved Plus Probable basis.

The purchase price was shared equally between the Company and Kiwetinohk, with each acquiring a 50% interest in the assets. Distinction’s portion of the Acquisition was financed with cash on hand and a new $127.5 million credit facility from a syndicate of lenders, which will be approximately 50% drawn to fund closing, including ATB Financial (as agent), Bank of Montreal and National Bank of Canada (the “New Credit Facility”). The New Credit Facility amends and restates the Company’s existing credit facility in its entirety and includes, among other amendments, the addition of a syndicated facility, the removal of the accordion feature and an extension of the maturity date to May 31, 2022.

ATB Capital Markets acted as financial advisor to Distinction on the Acquisition. McDaniel acted as a strategic advisor to Kiwetinohk on the Acquisition.

Related Transactions and Changes to the Board of Directors

In connection with the closing of the Acquisition, and pursuant to a settlement agreement (the “Settlement Agreement”) entered into on February 17, 2021, among Luminus Energy IE Designated Activity Company (“Luminus Energy”), 1266580 B.C. Ltd. (an affiliate of Luminus Energy) (“Luminus B.C.”), Kiwetinohk, the Company and Distinction Energy Partnership (“DEP”):

  • Messrs. P. Eric Gallie and Shawn Singh resigned from the board of directors of the Company (the “Board”) and were replaced with Messrs. Glenn Koach and Steven Sinclair;
    • Glenn Koach is the co-founder and principal of Concise Capital with over 35 years of experience in managing short-term, high-yield funds. As a corporate board director, Mr. Koach has guided several companies through difficult financial situations including, turn-arounds, workouts and bankruptcies. In addition, Mr. Koach is an experienced corporate executive holding key positions with both public and private companies, including serving as: CEO of Group Long Distance. Mr. Koach began his career as Senior Tax Specialist for Peat, Marwick, Mitchell & Co. and was a CPA. Mr. Koach holds a Bachelor of Science in Economics with a major in Finance and Accounting from the Wharton School at the University of Pennsylvania; and
    • Steven Sinclair is a corporate director who has over 35 years of senior operating and financial management experience with a number of publicly traded and private companies. Mr. Sinclair retired from his position of Senior Vice President and Chief Financial Officer of ARC Resources Ltd. in 2014 and currently is a Director and Chair of the Audit Committee of TransGlobe Energy Corporation and also a Director and Audit Committee chair of a Calgary headquartered private oil and gas company. Mr. Sinclair received his Bachelor of Commerce degree from the University of Calgary in 1978 and his Chartered Accountant’s designation in 1981.
  • Luminus B.C., Kiwetinohk and the Company entered into a participation agreement termination agreement, terminating the participation agreement entered into by such parties on October 16, 2020 in respect of the area of mutual interest described therein (the “AMI”).
  • Kiwetinohk, the Company and DEP entered into a further amended and restated management services agreement providing for the following amendments:
    • the timing of when fees are paid to Kiwetinohk (in its capacity as manager) in respect of management assistance services was amended from commencing on the receipt of conditional approval for the listing and posting for trading of the Company’s Class A common shares (the “Common Shares”) on the Toronto Stock Exchange, the TSX Venture Exchange or other comparable stock exchange or trading system (“Recognized Exchange”) as is approved by the Board (the “Listing”) to the date of the amended and restated management services agreement; and
    • the term of the amended and restated management services agreement was increased to a period of five years from the date of the amended and restated management services agreement, subject to earlier termination in certain circumstances and the Company’s ability to terminate such agreement was removed.                                
  • Luminus Energy, Kiwetinohk and the Company entered into a further amended and restated investor agreement providing for the following amendments:
    • Luminus Energy is now entitled to select one director nominee to serve on the Board, who is initially Tim Schneider, and Kiwetinohk is now entitled to select two director nominees, who are initially Kevin Brown and Pat Carlson, and Luminus Energy and Kiwetinohk shall agree upon two independent directors, who are Messrs. Glenn Koach and Steven Sinclair, to serve in that capacity until the next meeting of the shareholders of the Company at which directors of the Company are to be elected. After the next meeting of the shareholders of the Company at which directors of the Company are to be elected, the Board shall be reconstituted to be comprised of eight (8) members consisting of three directors nominees of Kiwetinohk, who shall initially be Kevin Brown, Pat Carlson, and Leland Corbett, two director nominees of Luminus Energy, who shall initially be Tim Schneider and Peter Eric Gallie, and three independent directors selected by Luminus Energy and Kiwetinohk, which director nomination entitlements may be reduced if Kiwetinohk or Luminus Energy holds less than 20% of the then issued and outstanding Common Shares;
    • the Board has established a listing committee for the purposes of pursuing and completing the Listing on a Recognized Exchange by the later of September 30, 2021 or the date unanimously determined by the listing committee (or failing unanimity, as determined by the Board) (the “Listing Committee”);
    • the officers of the Company shall be those proposed by Kiwetinohk’s director nominees; 
    • certain consent rights of Luminus Energy over fundamental actions of the Company have been removed such that the Company will only require the prior consent of Luminus Energy with respect to changing the composition of or the powers delegated to the Listing Committee, issuing additional securities or incurring any indebtedness other than indebtedness to be drawn down under the New Credit Facility; and
    • the provisions relating to the AMI, the restrictions on non-arm’s length transactions, and the reimbursement of certain expenses of Kiwetinohk, have been removed.
  • Luminus B.C. received an aggregate net $10 million payment from the Company (as to $5.75 million) and Kiwetinohk in connection with closing the transactions contemplated in the Settlement Agreement.

The summary of the provisions of the further amended and restated management services agreement and the further amended and restated investor agreement described above does not purport to be complete and is qualified in its entirety by reference to the provisions of such agreements, copies of which will be filed with the securities regulatory authorities in Canada and be available on Distinction’s SEDAR profile at www.sedar.com.

Early Warning Disclosure

The following disclosure is provided pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”) in connection with the filing of amended Early Warning Reports regarding the amendment and restatement of the investor agreement described above:

  • Luminus Energy: The amendment and restatement of the investor agreement reflects a material change to the disclosure in section 6 of the early warning report of Luminus Energy filed on October 16, 2020, as amended January 15, 2021 (the “Original Luminus Report”). Accordingly, pursuant to NI 62-103, Luminus Energy, of Rocktwist House, Block 1, Western Business Park, Shannon, Co. Clare V14 FW97, Ireland, reconfirms its early warning disclosure in the Company’s press release dated October 16, 2020, as amended January 15, 2021, as follows (with capitalized terms below having the same meaning given to them in such press releases): Luminus Energy acquired an aggregate of 2,601,167 Common Shares from the treasury of the Company pursuant to the Company’s recapitalization and financing transaction (the “Restructuring Transaction”) implemented as a plan of compromise and arrangement under the Companies’ Creditors Arrangement Act (Canada) and the Canada Business Corporations Act on October 16, 2020, representing approximately 42.7% of the issued and outstanding Common Shares (on an undiluted basis). Immediately prior to implementation of the Restructuring Transaction, Luminus Energy owned nil Common Shares and 33,204,500 warrants to purchase common shares (“Existing Warrants”), and indirectly owned 14,065,138 (57%) common shares (“Existing Shares”) of the Company through its indirect subsidiary, Luminus Delphi Holdings II Ltd. Upon implementation of the Restructuring Transaction, all 14,065,138 Existing Shares indirectly owned by Luminus Energy and all 33,204,500 Existing Warrants owned by Luminus Energy were cancelled for no consideration and without any return of capital. Luminus Energy acquired the Common Shares for investment purposes. Luminus Energy may acquire or dispose of additional securities of the Company in the future through the market, privately, or otherwise, as circumstances or market conditions warrant. A copy of the Early Warning Report reflecting the amendment to section 6 of the Original Luminus Report can be obtained on the Company’s SEDAR profile at www.sedar.com or from Luminus Energy c/o 1700 Broadway, 26th Floor, New York, NY, 10019 or phone: Shawn Singh at (212) 424-2889 or e-mail [email protected].

  • Kiwetinohk: The amendment and restatement of the investor agreement described above reflects a material change to the disclosure related thereto in the early warning report of Kiwetinohk filed on October 16, 2020, as amended on January 15, 2021 (the “Original Kiwetinohk Report”). Kiwetinohk, of 250 – 2 Street S.W., Suite 1900, Calgary, Alberta, T2P 0C1, initially acquired 1,522,181 Common Shares (the “Initial Acquired Common Shares”) from the treasury of the Company, representing 25% of the issued and outstanding Common Shares (on a non-diluted basis) as of the date of issuance, together with 3,348,799 purchase warrants to acquire Common Shares (the “Warrants”), which Warrants are collectively exercisable into such number of Common Shares as will result in Kiwetinohk holding 50%+1 of the Common Shares (on a fully diluted basis excluding any Common Shares issuable upon the exercise of any stock options to purchase Common Shares (“Options”)) as of the date of issuance (being 4,870,980 Common Shares assuming 9,741,959 issued and outstanding Common Shares (on a fully diluted basis excluding any Common Shares issuable upon the exercise of any Options and Special Warrants) and 304,436 Options outstanding at such time) upon satisfaction of certain conditions in the future and payment of an aggregate exercise price of $37,500,000, equal to $11.20 per Common Share (subject to certain adjustments in accordance with the terms of the Warrants) pursuant to the Restructuring Transaction. If any Options are exercised after the initial exercise date of the Warrants, the number of Warrants will be deemed increased on a 1:1 basis by the number of Options so exercised and the Warrants deemed issued shall also be exercisable for Common Shares at an exercise price of $11.20. The Initial Acquired Common Shares and Warrants were acquired for an aggregate purchase price of $22,916,670. On January 15, 2021, Kiwetinohk exercised the Warrants and pursuant thereto acquired 3,348,799 Common Shares (the “Additional Acquired Common Shares”) for an aggregate exercise price of $37,500,000 (prior to a working capital adjustment of $2,500,000 paid by Kiwetinohk to the Company) amounting to $11.20 per Additional Acquired Common Share. Prior to the completion of the Restructuring Transaction, Kiwetinohk did not own any securities of the Company. Immediately prior to the acquisition of the Additional Acquired Common Shares, Kiwetinohk owned 1,522,181 Common Shares representing 25% of the issued and outstanding Common Shares (on a non-diluted basis). Upon acquiring the Additional Acquired Common Shares, Kiwetinohk owned 4,870,980 Common Shares representing 51.61% of the issued and outstanding Common Shares (on a non-diluted basis or 50% +1 on a fully diluted basis excluding Common Shares issuable upon exercise of the Options). The acquisition of the Initial Acquired Common Shares and the Warrants by Kiwetinohk pursuant to the Restructuring Transaction and the acquisition of the Additional Acquired Common Shares pursuant to the exercise of the Warrants were each made for investment purposes. Kiwetinohk has a long-term view of the investments and subject to applicable law, Kiwetinohk may from time to time acquire additional securities of the Company or redeem, convert, exercise or otherwise dispose of the Initial Acquired Common Shares or the Additional Acquired Common Shares, in each case, including (without limitation) on the open market or through private dispositions in the future depending on market conditions, the terms of any such securities, reformulation of plans and/or other relevant factors. Kiwetinohk is an oil and gas company organized under the laws of the Province of Alberta with its head office located at: Suite 1900, 250 – 2nd Street SW, Calgary, Alberta T2P 0C1. A copy of the Early Warning Report reflecting the noted amendments to the Original Kiwetinohk Report with additional information in respect of the foregoing matters will be filed and made available on the Company’s SEDAR profile at www.sedar.com. To obtain a copy of such Early Warning Report, you may also contact Jakub Brogowski, Chief Financial Officer of Kiwetinohk at (587) 392-4416.

About Distinction Energy Corp.

Distinction Energy Corp. is a leading junior oil and gas company focused on liquids-rich natural gas produced primarily from the Montney formation. The Company achieved very attractive drilling results last year through the further development of its high quality Montney property, uniquely positioned in the Bigstone region of northwest Alberta. Distinction is headquartered in Calgary, Alberta.

FOR FURTHER INFORMATION PLEASE CONTACT:

DISTINCTION ENERGY CORP.

2300 – 333 – 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1
Telephone: (587) 392-4424 Facsimile: (587) 392-4425
Email: [email protected] Website: www.distinctionenergy.ca

PATRICK CARLSON

President & CEO
(403) 819-5090


Forward Looking Information

This press release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, the anticipated amount drawn under the New Credit Facility and statements related to “reserves” as they involve the implied assessment, based on certain estimates and assumptions, including that the reserves described can be profitably produced in the future. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. All forward-looking statements are made as of the date of this press release and the fact that this press release remains available does not constitute a representation by the Company that the Company believes these forward-looking statements continue to be true as of any subsequent date. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.


Disclosure of Oil and Gas Information

The use of the boe unit of measurement may be misleading, particularly if used in isolation. A boe conversion ratio of 6 mcf of natural gas to 1 barrel of oil is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. In addition, given that the value ratio based on the current price of oil as compared with natural gas is significantly different from the energy equivalent of six to one, utilizing a BOE conversion ratio of 6 Mcf: 1 bbl would be misleading as an indication of value. Distinction’s reported production is a mix of shale gas and natural gas liquids.

Proved reserves are those reserves that can be estimated with a high degree of certainty to be recoverable. It is likely that the actual remaining quantities recovered will exceed the estimated proved reserves. Probable reserves are those additional reserves that are less certain to be recovered than proved reserves. It is equally likely that the actual remaining quantities recovered will be greater or less than the sum of the estimated proved plus probable reserves. Proved developed producing reserves are those reserves that are expected to be recovered from completion intervals open at the time of the estimate. These reserves may be currently producing or, if shut-in, they must have previously been on production, and the date of resumption of production must be known with reasonable certainty. “MMboe” means million barrel of oil equivalent. “NPV10” means net present value discounted at 10%.

Estimates of net present value of future net revenue contained herein do not necessarily represent fair market value of reserves. Estimates of reserves, and future net revenue for individual properties may not reflect the same level of confidence as estimates of reserves and future net revenue for all properties, due to the effect of aggregation.
There is no assurance that the forecast price and cost assumptions applied by McDaniel in evaluating the reserves and future net revenue will be attained and variances could be material. There are numerous uncertainties inherent in estimating quantities of oil, natural gas and NGL reserves and cash flows to be derived therefrom, including many factors beyond Distinction’s control. Actual reserves, production and cash flows will vary from the estimates contained in the McDaniel report, and such variations could be material. In general, estimates of economically recoverable oil and natural gas reserves and the future net cash flows therefrom are based upon a number of variable factors and assumptions, such as historical production from the properties, production rates, ultimate reserve recovery, timing and amount of capital expenditures, marketability of oil and gas, royalty rates, the assumed effects of regulation by governmental agencies and future operating costs, all of which may vary from actual results. For those reasons, estimates of the economically recoverable oil and natural gas reserves attributable to any particular group of properties, classification of such reserves based on risk of recovery and estimates of future net revenues expected therefrom prepared by different engineers, or by the same engineers at different times, may vary. Distinction’s actual production, revenues, taxes and development and operating expenditures with respect to its reserves will vary from estimates thereof and such variations could be material. It should not be assumed that the estimates of future net revenue presented in this press release represent the fair market value of the reserves. The reserve and associated cash flow information set forth in the McDaniel report are estimates only and there is no guarantee that the estimated reserves will be recovered. Actual reserves may be greater than or less than the estimates provided therein.



Suburban Propane Donates to Growing Up New Mexico: The Early Childhood Partnership

Santa Fe Mayor Alan Webber Designates April 28th as Suburban Propane Day

PR Newswire

WHIPPANY, N.J., April 28, 2021 /PRNewswire/ — Suburban Propane Partners, L.P. (NYSE: SPH), a nationwide distributor of propane, renewable propane, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, has made a donation to Growing Up New Mexico: The Early Childhood Partnership in Santa Fe, NM, providing 500 Spanish-language books and more than 100 educational, developmentally-appropriate toys. Santa Fe Mayor Alan Webber presented Suburban Propane with a congratulatory proclamation, which designated the day as ‘Suburban Propane Day’ also marking Suburban Propane’s second anniversary in Santa Fe. 

“I want to express my great appreciation to Suburban Propane for making such a generous contribution to the kids of Santa Fe,” said Mayor Alan Webber. “Suburban Propane recognizes the big difference that Spanish-language books and toys that nurture development can make in the life of a young person. It means a lot for the company to give that kind of support to our families and we’re enormously grateful.”

“Thank You Mayor Webber, we are tremendously honored to serve the state of New Mexico and by your proclamation of declaring April 28, 2021 as Suburban Propane Day. Giving back to our local communities is the cornerstone of our SuburbanCares commitment,” said Nandini Sankara, Spokesperson for Suburban Propane. “It’s gratifying to join forces with Growing Up New Mexico to make a difference and donating books and toys to young children in the underserved communities of Santa Fe.”

This initiative is part of Suburban Propane’s SuburbanCares platform which is dedicated to supporting community efforts across their footprint in the United States. This year, Suburban Propane is undertaking initiatives to help children in underserved communities, including in Philadelphia, PA; Santa Rosa, CA; Charleston, SC; Detroit, MI; Worcester, MA; and New Brunswick, NJ.  In addition, the SuburbanCares corporate pillar has focused on giving back to the frontline healthcare professionals by providing meals in some of the most COVID-19 affected regions in the nation; including Florida, California, Texas, Maryland, New Jersey, New York and Washington, DC.

“We thank Suburban Propane for their generosity. At Growing Up New Mexico, we have programs for families and childcare providers with children under 5 years old. Our commitment is to provide developmental toys that demonstrate the creativity and resourcefulness of children. We also mail children’s books in Spanish to over 500 families quarterly to encourage communication and learning for our bilingual and Spanish language home environments,” said Abby Bordner, Vice President of Development, Growing Up New Mexico: The Early Childhood Partnership. “SuburbanCares has helped us provide the essential tools to help families support early learning and we thank them for their support.”


About Suburban Propane:

Suburban Propane Partners, L.P. (NYSE:SPH), a nationwide distributor of propane, renewable propane, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, servicing over 1 million customers through its 700 locations across 41 states. The company proudly celebrated 90 years of innovation, growth and quality service in 2018. The brand is currently focused on three core elements including Suburban Commitment – showcasing the company’s 90+ year legacy of flexibility, reliability and dependability, Suburban Cares – highlighting dedication to serving local communities across the nation and Go Green with Suburban Propane – promoting the affordable, clean burning and versatile nature of propane as a bridge to a green energy future. Suburban Propane is a New York Stock Exchange listed limited partnership headquartered in Whippany, NJ.

For additional information on Suburban Propane, please visit https://www.suburbanpropane.com/.  


About Growing up New Mexico: The Early Childhood Partnership

Growing up New Mexico’s mission is to engage the whole community, bringing together people and resources to create increased opportunities for children and families to achieve their dreams and aspirations. They envision a community where all children succeed in school and life. Their strategy is to employ a multi-generation approach, supporting both children and their families in a series of high-quality early childhood programs designed to prepare children to enter kindergarten ready to succeed. Growing Up New Mexico also influences statewide policy that prioritizes children, prenatal through age five, and the adults in their lives.

In partnership with the Santa Fe Public Schools, Growing Up New Mexico has purchased the former Kaune Elementary School in the Casa Linda neighborhood. This site is the home of the newly opened Early Learning Center at Kaune which provides high-quality, full-day, dual-language Early PreK and PreK to three and four-year-olds.

For additional information, visit https://growingupnm.org.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/suburban-propane-donates-to-growing-up-new-mexico-the-early-childhood-partnership-301279613.html

SOURCE Suburban Propane Partners, L.P.

Date Change for Cogent Communications Earnings Release

PR Newswire

WASHINGTON, April 28, 2021 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) today announced that its press release disclosing Cogent’s operating results for the first quarter of 2021 will be issued at 5:20 p.m. (ET) on April 28, 2021.

The date and time for the conference call to present Cogent’s operating results for the first quarter of 2021 and answer questions, is unchanged and will still take place at 8:30 a.m. (ET) on April 29, 2021.

Participation on the conference call is open to all parties and the call may be accessed as follows:

Dial-in Numbers:  

1-800-668-4132 for U.S. callers

1-224-357-2196 for international callers

We recommend callers dial in 15 minutes prior to the start of the call to ensure you are connected.

Internet:

An audio webcast is accessible under “Events” in the “News” section of Cogent’s website at www.cogentco.com/events and will remain available through May 19, 2021. A printed transcript will be posted on the website when it becomes available.

Telephone Replay: 

Thursday, April 29, 2021 at 12:00 p.m. (ET) and continuing through 12:00 p.m. (ET) on Thursday, May 6, 2021. 

To listen to the replay, please dial 1-404-537-3406, Access code 3771788

About Cogent

Cogent (NASDAQ: CCOI) is a facilities-based provider of low cost, high speed Internet access and private network services to bandwidth intensive businesses. Cogent’s facilities-based, all-optical IP network provides services in 210 markets across 48 countries.

Cogent is headquartered at 2450 N Street, NW, Washington, D.C. 20037. For more information, visit www.cogentco.com. Cogent can be reached in the United States at (202) 295-4200 or via email at [email protected].

Information in this release may involve expectations, beliefs, plans, intentions or strategies regarding the future.  These forward-looking statements involve risks and uncertainties.  All forward-looking statements included in this release are based upon information available to Cogent Communications Holdings, Inc. as of the date of the release, and we assume no obligation to update any such forward-looking statement.  The statements in this release are not guarantees of future performance and actual results could differ materially from our current expectations.  Numerous factors could cause or contribute to such differences.  Some of the factors and risks associated with our business are discussed in Cogent’s registration statements filed with the Securities and Exchange Commission and in its other reports filed from time to time with the SEC.

 

Cision View original content:http://www.prnewswire.com/news-releases/date-change-for-cogent-communications-earnings-release-301279610.html

SOURCE Cogent Communications Holdings, Inc.

New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease

Program Evaluated the Safety and Efficacy of Vadadustat in Adult Patients with Anemia Due to CKD on Dialysis and Not on Dialysis

PR Newswire

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ — Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis (INNO2VATE) and adult patients not on dialysis (PRO2TECT) in two separate manuscripts.  

Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is Akebia’s lead product candidate. In late March 2021, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis and adult patients not on dialysis.

“Having recently submitted our NDA for vadadustat, we are proud to have the results of our global Phase 3 clinical program published in the prestigious New England Journal of Medicine for review by the broader medical community,” said Steven K. Burke, M.D., Chief Medical Officer of Akebia Therapeutics. “The publications, authored by members of the independent Executive Steering Committee in collaboration with trial investigators and Akebia, are a testament to the work of these team members who designed this program after extensive dialogue with the FDA and European regulators. We extend our deepest appreciation to everyone involved in this program, including the physicians, investigators, site coordinators, and, most importantly, the nearly 7,500 patients who participated.”

“The kidney community has been eagerly awaiting peer-reviewed publication of comprehensive and straight-forward analyses of cardiovascular safety and hematological efficacy results of a Phase 3 program evaluating the treatment of anemia associated with CKD with a novel HIF-PHI,” said Glenn Chertow, M.D., M.P.H., Professor of Medicine at Stanford University School of Medicine, lead author of one of the manuscripts and Co-Chair of the independent Executive Steering Committee for the vadadustat global Phase 3 program. “We are honored to have vadadustat’s global Phase 3 clinical program published in the New England Journal of Medicine. These publications reflect the clinical relevance, scientific rigor and transparency of the vadadustat development program.”

Kai-Uwe Eckardt, M.D., Professor of Medicine and Head of the Department of Nephrology and Medical Intensive Care at the Charité in Berlin, Germany, and Co-Chair of the independent Executive Steering Committee for the vadadustat global Phase 3 program, is the lead author of the INNO2VATE manuscript titled, “Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.” The manuscript states, “Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and maintenance of hemoglobin concentrations.”

Dr. Chertow is the lead author of the PRO2TECT manuscript titled, “Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD,” which states, “Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety.


The New England Journal of Medicine
 is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase 3 clinical development program for the treatment of anemia due to CKD. Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan’s Ministry of Health, Labour and Welfare (MHLW). In Japan, vadadustat is approved and marketed under the tradename Vafseo™, as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.

About Anemia due to Chronic Kidney Disease (CKD) 
Anemia is a condition in which a person lacks enough healthy red blood cells to carry adequate oxygen to the body’s tissues. It commonly occurs in people with CKD because their kidneys do not produce enough erythropoietin (EPO), a hormone that helps regulate production of red blood cells. Anemia due to CKD can have a profound impact on a person’s quality of life as it can cause fatigue, dizziness, shortness of breath and cognitive dysfunction. Left untreated, anemia leads to deterioration in health and is associated with increased morbidity and mortality in people with CKD.

Investor Contact

Kristen K. Sheppard, Esq.

[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-of-global-phase-3-clinical-program-of-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-301279608.html

SOURCE Akebia Therapeutics